Department of Medicine and Clinical Oncology, Chiba University Graduate School of Medicine, Chuou-ku, Japan.
Br J Radiol. 2012 May;85(1013):587-95. doi: 10.1259/bjr/25522379. Epub 2011 Feb 22.
The aim of this prospective study was to elucidate the efficacy of contrast-enhanced three-dimensional (3D) ultrasound with Sonazoid(®) (GF Healthcare, Oslo, Norway) as a non-invasive tool to discriminate idiopathic portal hypertension (IPH) from cirrhosis by demonstration of portal vein structure.
There were 16 patients: 11 with biopsy-proven cirrhosis and 5 with biopsy-proven IPH. Intrahepatic right portal vein images were taken by 3D ultrasound from 1 min after the injection of Sonazoid (0.0075 ml kg(-1)). Portal vein appearances were compared between 3D ultrasound and percutaneous transhepatic portography (PTP) by four independent reviewers. Sensitivity, specificity and area under the receiver operating characteristic curve (Az) of the images were used for the diagnosis of cirrhosis/IPH, and interimaging, inter-reviewer and interoperator agreement were examined.
Sensitivity, specificity and Az of PTP for the diagnosis of cirrhosis/IPH were 63.6%/100%, 100% and 0.9 (0.71-1.0) by Reviewer I and 90.9%/100%, 100% and 1.0 by Reviewer III, respectively. Similarly, sensitivity, specificity and Az of 3D ultrasound for diagnosis of cirrhosis/IPH were 54.5%/80%, 100% and 0.96 (0.84-1.0) by Reviewer II and 72.7%/80%, 100% and 0.97 (0.9-1.0) by Reviewer IV, respectively. Diagnostic agreement between PTP and 3D ultrasound was good between Reviewers I and II (κ=0.793) and good between Reviewers III and IV (κ=0.732). Inter-reviewer agreement was good between Reviewers I and III for PTP diagnosis (κ=0.735), and good between Reviewers II and IV for 3D ultrasound diagnosis (κ=0.792). Interoperator agreement of diagnostic results was good (κ=0.740).
Non-invasive visualisation of intrahepatic portal vein structure by contrast-enhanced 3D ultrasound with Sonazoid may have the potential to discriminate IPH from cirrhosis.
本前瞻性研究旨在通过显示门静脉结构,阐明使用 SonoVue(®)(GF Healthcare,挪威奥斯陆)增强的三维(3D)超声作为一种非侵入性工具来区分特发性门静脉高压(IPH)和肝硬化的疗效。
共有 16 名患者:11 名经活检证实为肝硬化,5 名经活检证实为 IPH。在 SonoVue(0.0075ml/kg)注射后 1 分钟,通过 3D 超声获取肝内右门静脉图像。由四位独立的评审员比较 3D 超声和经皮经肝门静脉造影术(PTP)的门静脉表现。使用图像诊断肝硬化/IPH 的灵敏度、特异性和接收者操作特征曲线下面积(Az),并检查中期成像、评审员间和操作者间的一致性。
PTP 对肝硬化/IPH 的诊断的灵敏度、特异性和 Az 分别为 Reviewer I 的 63.6%/100%、100%和 0.9(0.71-1.0),以及 Reviewer III 的 90.9%/100%、100%和 1.0。同样,3D 超声对肝硬化/IPH 的诊断的灵敏度、特异性和 Az 分别为 Reviewer II 的 54.5%/80%、100%和 0.96(0.84-1.0),以及 Reviewer IV 的 72.7%/80%、100%和 0.97(0.9-1.0)。PTP 和 3D 超声之间的诊断一致性在 Reviewer I 和 II 之间良好(κ=0.793),在 Reviewer III 和 IV 之间良好(κ=0.732)。PTP 诊断的 Reviewer I 和 III 之间的评审员间一致性良好(κ=0.735),3D 超声诊断的 Reviewer II 和 IV 之间的评审员间一致性良好(κ=0.792)。诊断结果的操作者间一致性良好(κ=0.740)。
使用 SonoVue 增强的 3D 超声非侵入性可视化肝内门静脉结构可能有潜力区分 IPH 和肝硬化。